×
Hero Background

Primary Aldosteronism Companies

ID: MRFR/Pharma/4075-HCR
90 Pages
Rahul Gotadki
October 2025

Primary Aldosteronism, a condition characterized by overproduction of aldosterone by the adrenal glands, requires careful management and treatment. Several pharmaceutical companies play a crucial role in developing and providing medications for the treatment of Primary Aldosteronism. 

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Primary Aldosteronism Market Research Report – Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Primary Aldosteronism Market

Primary Aldosteronism Market

 


Latest Primary Aldosteronism Companies Updates:


Novartis expands access to Mineralo (spironolactone) Offering the medication in more dosage forms and launching patient support programs improves medication adherence and treatment outcomes.


Abbott receives FDA approval for AlinIQ Analyzer for rapid aldosterone testing This point-of-care technology allows for fast and accurate aldosterone level measurement, facilitating quicker diagnosis and treatment decisions.


Research on next-generation mineralocorticoid receptor antagonists Companies like Boehringer Ingelheim are developing new medications with improved side effect profiles and potentially longer-lasting effects for better PA management.


List of Primary Aldosteronism Key companies in the market:



  • Canon Inc 

  • Pfizer Inc.

  • Shimadzu Corporation 

  • Sun Pharmaceutical Industries Ltd.

  • Shimadzu Corporation

  • Bristol Laboratories Ltd

  • Siemens AG

  • Bristol Laboratories Ltd